PDCD1 and ovarian carcinoma: In addition, the majority of HGSOC patients derive no significant benefit from clinically available immunotherapies, as numerous clinical trials have demonstrated low response rates to programmed cell death protein 1 (PD-1) based therapies (James et al., 2020), despite the fact that intratumoral T cells are known to be highly prognostic in ovarian cancer (Zhang et al., 2003; Hwang et al., 2012).